TrialAnnals of hematology2020

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.

Sang Eun Yoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.